The development of pyrrolobenzodiazepines as antitumour agents.
about
An Update on the Synthesis of Pyrrolo[1,4]benzodiazepinesProgress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery SystemsAntibody-drug conjugates as novel anti-cancer chemotherapeuticsPyrrolobenzodiazepines (PBDs) do not bind to DNA G-quadruplexesChemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug ConjugatesDNA sequence-selective C8-linked pyrrolobenzodiazepine-heterocyclic polyamide conjugates show anti-tubercular-specific activities.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineeringEvidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.Enterotoxicity of a nonribosomal peptide causes antibiotic-associated colitis.Complexity in the binding of minor groove agents: netropsin has two thermodynamically different DNA binding modes at a single site.Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.Site-specific antibody drug conjugates for cancer therapyAntibody-drug conjugates - a perfect synergy.Antibody-drug conjugates for the treatment of cancer.Drug delivery and release systems for targeted tumor therapy.In vivo biotransformations of antibody-drug conjugates.Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.Antibody-drug conjugates: recent advances in conjugation and linker chemistries.Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging.Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates.Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.Biosynthesis of the Enterotoxic Pyrrolobenzodiazepine Natural Product Tilivalline.Synthesis and biological activity of fused tetracyclic Pyrrolo[2,1-c][1,4]benzodiazepines.A rapid screen for molecules that form duplex to duplex crosslinks in DNA.Antibody-Drug Conjugates for Cancer Therapy.Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.DNA damaging agent-based antibody-drug conjugates for cancer therapy
P2860
Q26772938-E794ACBA-ECD0-43FB-8115-1A3D806E6BBDQ26782485-61D42D11-DC3D-4E2C-8893-4A08A99AAE5FQ26800175-D9760B80-30CE-49E5-BCA7-FA9101CC6157Q28542060-185412C9-0AAA-4CFE-AB4B-5193EB5284BDQ28828981-2D179191-C88A-4B79-8AE6-04B736D87D12Q30387972-C7DFD62D-D991-4B31-B0EE-5BF6DB417939Q33410375-36F8FC96-32C3-4869-A9DC-C09932AB86C0Q33587970-A8DDE035-34F8-4D8D-A7A3-0807C509EB69Q34424018-CE584993-C036-4817-A790-A37B083976D2Q34583682-6A71B419-4A97-44EF-8F62-83341B5479F0Q35617220-1E110F81-9296-4090-80C5-79DF0249A188Q35748135-B6EE10A7-1EF3-40F0-9F80-C774F74B5114Q37593705-DD75CC84-3269-4BFA-BDBF-E59C1FDD2446Q38014923-ED951405-526A-4ED2-A6A9-CB4829A10612Q38068568-81423B3B-D998-415F-9F5E-8F8EA73CF744Q38363691-93F56B4D-236B-4D0D-A7DB-38A6F33B8CF6Q38557525-4701FD28-89DD-4F8E-93DC-97196A1E7E63Q38708078-E1CE125E-4418-46E6-A427-D366F344F2EDQ38981429-E29F9E66-0A2C-4B75-BB49-001BAEE14A01Q40347587-4BDC4F20-6999-4BA6-A7C4-5D8B7576F1ACQ42871498-8DBF1268-06A8-4301-94EB-742CF45CEE62Q46352637-BFA95EAB-0049-47B1-9483-1C04E9AA0468Q47139670-9C7D588A-C859-41AF-BB5A-AF870C2FF9CFQ47424110-B0A1C074-DA94-41F4-BABF-DF76D7EE6BEFQ52645748-9CBBB989-C170-4C16-B07A-72FB23785B71Q53317635-DEB4991A-90E4-466A-98F9-D6D31D979FD6Q53739135-92A0CE12-F06D-4E53-939E-EE86E4EE92C0Q55109090-870A8182-D1E4-4F76-826D-EA676999D49AQ57192403-6737F8A3-258D-44E2-8049-C2E06903E107
P2860
The development of pyrrolobenzodiazepines as antitumour agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The development of pyrrolobenzodiazepines as antitumour agents.
@en
The development of pyrrolobenzodiazepines as antitumour agents.
@nl
type
label
The development of pyrrolobenzodiazepines as antitumour agents.
@en
The development of pyrrolobenzodiazepines as antitumour agents.
@nl
prefLabel
The development of pyrrolobenzodiazepines as antitumour agents.
@en
The development of pyrrolobenzodiazepines as antitumour agents.
@nl
P2860
P1476
The development of pyrrolobenzodiazepines as antitumour agents.
@en
P2093
John A Hartley
P2860
P304
P356
10.1517/13543784.2011.573477
P407
P577
2011-04-04T00:00:00Z